<DOC>
	<DOCNO>NCT00003240</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It know whether give chemotherapy addition standard therapy effective treatment lung cancer . PURPOSE : Randomized phase III trial compare effectiveness standard therapy give without combination chemotherapy treat patient non-small cell lung cancer .</brief_summary>
	<brief_title>Standard Therapy Given With Without Combination Chemotherapy Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess whether addition cisplatin-based chemotherapy standard treatment improve survival patient non-small cell lung cancer . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . Arm I : Patients undergo primary surgery , radical radiotherapy , radiotherapy surgery , best supportive care . Arm II : Patients undergo treatment arm I . Beginning within 10 week surgery radical radiotherapy soon possible diagnosis , patient receive 1 follow regimen : Regimen A : Patients receive cisplatin IV day 1 follow vindesine day 1 8 . Regimen B : Patients receive mitomycin , ifosfamide , cisplatin day 1 . Regimen C : Patients receive mitomycin , vinblastine , cisplatin day 1 . Regimen D : Patients receive vinorelbine day 1 8 cisplatin day 1 . Treatment 4 regimen repeat every 3 week 3 course . Patients follow 3 month , 6 month , 1 year , annually thereafter . PROJECTED ACCRUAL : A total 1,800 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer treat primary surgery , radical radiotherapy , surgery plus radiotherapy , best supportive care PATIENT CHARACTERISTICS : Age : Adult Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : No inadequate renal function Other : No prior concurrent malignancy within past 3 year except nonmelanoma skin cancer Must fit enough receive therapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Prior radical radiotherapy allow Surgery : See Disease Characteristics Prior surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>